Bacteriostatic and bactericidal activity of levofloxacin against clinical isolates from cystic fibrosis patients

European Journal of Clinical Microbiology and Infectious Diseases

Volumn 23, Issue 10, 2004, Pages 798-800

  Golini, G ^a   Favari, F ^b   Marchetti, F ^c   Fontana, R ^a  

^a UNIVERSITY OF VERONA   (Italy)

^b UNIVERSITY HOSPITAL OF VERONA   (Italy)

^c GSK   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

CEFTAZIDIME; CIPROFLOXACIN; LEVOFLOXACIN; MEROPENEM; PIPERACILLIN; QUINOLINE DERIVED ANTIINFECTIVE AGENT;

ARTICLE; BACTERIAL STRAIN; BACTERICIDAL ACTIVITY; BACTERIOSTASIS; BACTERIUM CULTURE; BACTERIUM ISOLATION; BURKHOLDERIA CEPACIA; CONTROLLED STUDY; CYSTIC FIBROSIS; DRUG BLOOD LEVEL; ENTEROBACTERIACEAE; HAEMOPHILUS INFLUENZAE; HUMAN; INOCULATION; NONHUMAN; PRIORITY JOURNAL; PSEUDOMONAS AERUGINOSA; STAPHYLOCOCCUS AUREUS;

ANTI-BACTERIAL AGENTS; BURKHOLDERIA CEPACIA; CYSTIC FIBROSIS; DRUG RESISTANCE, BACTERIAL; HAEMOPHILUS INFLUENZAE; HUMANS; MICROBIAL SENSITIVITY TESTS; OFLOXACIN; PSEUDOMONAS AERUGINOSA; STAPHYLOCOCCUS AUREUS;

EID: 8744269980     PISSN: 09349723     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10096-004-1216-3     Document Type: Article

References (11)

1. Gilligan PH (1991) Microbiology of airway disease in patients with cystic fibrosis. Clin Microbiol Rev 4:35-51
2. Govan JRW, Deretic V (1996) Microbial pathogenesis in cystic fibrosis: mucoid Pseudomonas aeruginosa and Burkholderia cepacia. Microbiol Rev 60:539-574
3. Hurst M, Lamb HM, Scott LJ, Figgitt DP (2002) Levofloxacin. A review on its clinical use. Drugs 62:2127-2167
4. Marchetti F, Viale P (2003) Current and future perspectives of levofloxacin in the treatment of severe Pseudomonas aeruginosa infections. J Chemother 15:315-322
5. National Committee for Clinical Laboratory Standards (1999) National Committee for Clinical Laboratory Standards Performance standards for antimicrobial susceptibility testing. Ninth informational supplement. Approved standard M100-S9. NCCLS, Wayne
6. Amsterdam D (1991) Susceptibily testing of antimicrobials in liquid media. In: Lorian V (ed) Antibiotics in laboratory medicine. Williams and Wilkins, Baltimore, pp 53-105
7. Segatore B, Setacci D, Perilli M, Franceschini N, De Sanctis A, Marchetti F, Amicosante G (1999) Italian survey on the comparative levofloxacin susceptibility in 334 clinical isolates of Pseudomonas aeruginosa. Antimicrob Agents Chemother 43:428-431
8. Drago L, De Vecchi E, Nicola L, Valli M, Marchetti M, Gismondo MR (2003) Comparative bactericidal activity of fluoroquinolones against clinical isolates resistant to fluoroquinolones. J Chemother 15:118-124
9. Segatore B, Setacci D, Franceschini N, Marchetti F, Amicosante G (2000) Bactericidal activity of levofloxacin and ciprofloxacin on different phenotypes of Pseudomonas aeruginosa clinical isolates. Int J Antimicrob Agents Chemother 13:223-226
10. Preston SL, Drusano GL, Berman AL et al (1998) Pharmacodynamics of levofloxacin: a new paradigm for early clinical trials. J Am Med Assoc 125-129
11. Gotfried MH, Danziger LH, Rodvold KA (2001) Steady state plasma and intrapulmonary concentrations of levofloxacin and ciprofloxacin in healthy adult subjects. Chest 119:1114-1122